

# 個人履歷

姓名: 黃耀南

職稱: 助理教授

任職機構: 澳門科技大學

電話: (+853) 88971776

電郵: inwong@must.edu.mo

ORCID: 0000-0002-4500-1758

地址: 澳門路環擎天匯 R 鋪澳門科技大學醫學院 209D 室



## 人員簡介

黃耀南博士自 2019 年 7 月起擔任澳門科技大學醫學院助理教授。他於 2006 年從北京師範大學獲得生物學學士學位。隨後於 2007 年在謝菲爾德大學分子醫學（遺傳學）領域獲得碩士學位，並以第一名的成績畢業。2012 年，他在謝菲爾德大學以畢業論文毋須作任何修改的成績完成答辯並獲得醫學博士學位。在加入澳門科技大學之前，黃博士曾在謝菲爾德大學和牛津大學擔任博士後研究員。期間，他運用蛋白質生物化學、結構生物學、細胞生物學和蛋白質組學等先進技術，成功發現了病毒和人體中新 DNA 複製和修復因子。這些研究成果已發表在 *Nucleic Acid Res.*, *eLife*, *Sci. Rep.* 等知名期刊上。

目前，黃博士專注於尋找用於治療癌症、神經退行性疾病、免疫調節，並具有潛在臨床應用價值的天然化合物，同時探究其作用的分子機理。同時，他亦探索醫學人工智能的臨床應用，包括建立人類全週期生物鐘模型，以加深對晝夜節律對疾病與治療影響的理解，並研發用於臨床決策支援的 AI 工具。透過結合天然產物研究與計算及 AI 方法，加速從分子水平到臨床落地的轉化。其近期成果發表於 *Nat. Med.*, *Trends Mol. Med.*, *J. Transl. Med.*, *Chin. Med. J.*, *Pharmacol. Res.*, *Biomark. Res.*, *Food Chem.:X* and *Int. J. Biol. Macromol.* 等期刊上。此外，他被任命為澳門特區政府委任為生命科學道德委員會成員，亦曾任人才發展委員會「大健康」產業專責小組成員。

## 學歷

2012 年 6 月：英國謝菲爾德大學醫學博士學位 (Outright Pass)

2007 年 11 月：英國謝菲爾德大學分子醫學(遺傳)碩士學位 (Distinction; Rank: 1st)

2006 年 7 月：北京師範大學生物學學士學位

## 工作經驗

2019 年 7 月至今：澳門科技大學助理教授  
2013 年 9 月–2019 年 5 月：英國牛津大學博士後研究員  
2012 年 5 月–2013 年 9 月：英國謝菲爾德大學博士後研究員  
2007 年 2 月–2008 年 8 月：英國謝菲爾德大學實驗室技術員

## 個人獎項

2008 年–2012 年：英國謝菲爾德大學博士獎學金  
2006 年–2007 年：澳門高等教育局研究生獎學金  
2002 年–2006 年：澳門教育暨青年局大專獎學金  
2002 年：澳門蓮花獎  
1999 年：澳門總督獎

## 當前的學術和社會任職

2025 年 2 月至今：澳門特區政府生命科學道德委員會成員  
2023 年 7 月–2025 年 6 月：澳門特區政府人才發展委員會大健康產業專責小組成員  
2025 年 3 月至今：澳門科技大學醫學倫理委員會成員  
2024 年 8 月至今：澳門科技大學臨床倫理委員會成員  
2019 年 8 月至今：澳門科技大學學術誠信委員會成員  
2019 年 8 月至今：澳門科技大學學生紀律獎懲委員會委員  
2019 年 7 月–2020 年 8 月：澳門科技大學醫藥綜合教學實驗管理委員會委員

## 研究項目

- 2025 年 5 月–2028 年 5 月: FDCT, **Wong Io Nam (PI)**, 總狀蕨藻硫酸多糖介導 DNA 損傷修復途徑提高微衛星穩定型 (MSS) 胃癌治療效果的機制研究與應用探索, 項目編號 0133/2024/RIA2, MOP\$ 1,700,900
- 2021 年 9 月–2024 年 9 月: FDCT-NSFC, **Wong Io Nam (PI)**, 蕨藻硫酸多糖靶向 COX-2 介導的鐵死亡重塑免疫代謝的分子機制研究, 項目編號 0069/2021/AFJ, MOP\$ 1,600,000
- 2022 年 2 月–2023 年 8 月: FRG, **Wong Io Nam (PI)**, 利用 BioID 鄰位生物素標記的方法去探究與 SV40 宿主抑制因子 FAM111A 相互作用的潛在新的促病毒和抗病毒因子之特性, 項目編號 FRG-22-022-FMD, MOP \$100,000
- 2024 年 6 月–2027 年 6 月: FDCT-AKP, Paul Kwong-Hang Tam (PI), Chen Yan

(Co-PI), **Wong Io Nam (Member)**, 結合再生醫學,多組學及人工智能平台開展改善慢性肝病纖維化的標靶發現及精準干預新診療, 項目編號 0011/2023/AKP, MOP\$ 11,917,000

5. 2022 年 12 月–2025 年 6 月: FDCT-ITP, Simon Wing Fai Mok (PI), **Wong Io Nam (Co-PI)**, Vincent Kam Wai Wong (Co-PI), 揭示 p53 聚合體在類風濕性關節炎病理發展中的調節作用, 項目編號 0037/2022/ITP, MOP \$425,000
6. 2022 年 4 月–2025 年 4 月: FDCT, Olivia Monteiro (PI), **Wong Io Nam (Co-PI)**, Brian Tomlinson (Co-I), Christopher Wai Kei Lam (Co-I), 研究國藥滅活疫苗 BBIBP-CorV 和 BioNTech mRNA 疫苗初種系列及同源與異源加強劑在澳門地區人群中對新冠肺炎病毒株的有效性, 項目編號 0106/2021/A, MOP \$644,000
7. 2020 年 9 月–2023 年 9 月: FDCT-NSFC, Zhang Kang (PI), **Wong Io Nam (Co-PI)**, Simon Wing Fai Mok (Co-I), 結膜幹細胞轉化類角膜緣幹細胞與角膜重建, 項目編號 0007/2020/AFJ, MOP\$ 2,000,000

#### 學術出版物

1. Xia X, Wu Y, Chen Z, Du D, Chen X, Zhang R, Yan J, **Wong IN\***, Huang R, An edible green algae polysaccharide CRVP from *Caulerpa racemosa* var. *peltate* induced apoptosis of liver cancer cells Hepa1-6 by regulating glutathione metabolism (2025). *Food Sci Hum Wellness*, DOI: 10.26599/FSHW.2024.9250300. (\* corresponding author, IF 7.4, SCI Q1)
2. Li G, Cheng L, **Wong IN\***, Yin Y, Chen J, Liu L, Zhang K. Predicting healthspan and disease risks through biological age (2025). *Trends Mol Med*, DOI: 10.1016/j.molmed.2025.10.006. (\*first author, IF 13.8, SCI Q1)
3. Zhong J, Chung SK, Han X, Huang R, Xu B, **Wong IN** (2025). *Front Pharmacol*, DOI: 10.3389/fphar.2025.1682025. (Corresponding author, IF 4.8, SCI Q1)
4. Wang K, Liu F, Wu W, Hu H, Shen X, Wang M, Li G, Zeng F, Liu L, **Wong IN**, Liu S, Zou Z, Li B, Li J, Huang X, Jin S, Li Z, Xu H, Chen G, Chen X, Zhu Y, Li P, Feng Z, Wang W. A full life cycle biological clock based on routine clinical data and its impact in health and diseases (2025). *Nat Med*, DOI: 10.1038/s41591-025-04006-w. (second author, IF 50.0, SCI Q1)
5. Liu F, Niu Y, Zhang Q, Kang K, Dong Z, **Wong IN**, Cheng L, Li T, Duan L, Li K, Li G, Hou TW, Fok M, Luo Hu, Chen X, Zhang K, Yin Y. A foundational architecture for AI agents in healthcare (2025). *Cell Rep Med*, DOI: 10.1016/j.xcrm.2025.102374. (sixth author, IF 10.6, SCI Q1)
6. Huang C, Xiao Y, Xu D, **Wong IN**, Patil NG, Chen J, Zhang K, Hu W, Zhang J, Ding S, Kuang M, Xiao H, Feng X. Developing a Student-Centred Curriculum: Insights from Anaesthetic Placement Experiences for Co-Designing in China's

- Greater Bay Area (2025). *Adv medical educ pract.*, 16, 1695-1704. (second author, IF 1.7, ESCI Q2)
7. Yang L, Mok SWF, Li HH, **Wong IN\***, Yang LJ. DDX27 in cancer: molecular mechanisms, clinical implications, and therapeutic potential (2025). *J Transl Med*, 23, 971. (\* corresponding author, IF 7.5, SCI Q1)
  8. Qu L, Tang Y, Wu J, Yun X, Lo HH, Song L, Wang X, Wang H, Zhang R, Liu M, Wang C, Ng JPL, Fu X, **Wong IN\***, Wong VKW, Law BYK, FBXL16: a new regulator of neuroinflammation and cognition in Alzheimer's disease through the ubiquitination-dependent degradation of amyloid precursor protein (2024). *Biomark Res.*, 12, 144. (\* corresponding author, IF 11.5, SCI Q1)
  9. **Wong IN**, Monteiro O, Baptista-Hon DT, Wang K, Lu W, Sun Z, Nie S, Yin Y, Leveraging foundation and large language models in medical artificial intelligence (2024). *Chin Med J*. DOI:10.1097/ CM9.0000000000003302. (first author, IF 7.3, SCI Q1)
  10. Zeng J, Liu J, Zhao N, **Wong IN\***, Huang R, Caulerpa chemnitzia polysaccharide exerts immunomodulatory activity in macrophages by mediating the succinate/PHD2/HIF-1 $\alpha$ /IL-1 $\beta$  pathway, (2024). *Int J Biol Macromol.*, 2024 Oct: 134450. (\* corresponding author, IF 8.5, SCI Q1)
  11. Qin B, Fu S, Xu X, Yang J, Wang Y, Wang L, Huang B, Zhang J, Wu W, Lu H, Law BYK, Wang N, **Wong IN\***, Wong VKW, Far-infrared radiation and its therapeutic parameters: A superior alternative for future regenerative medicine? (2024). *Pharmacol Res.*, 208 : 107349. (\* corresponding author, IF 10.5, SCI Q1)
  12. Wang XX, Ji X, Lin J, **Wong IN**, Lo HH, Wang J, Qu L, Wong VKW, Chung SK, Law BYK, GPCR-mediated natural products and compounds: Potential therapeutic targets for the treatment of neurological diseases (2024). *Pharmacol Res.*, 208: 107395. (second author, IF 10.5, SCI Q1)
  13. Zhang J, Tang Y, Feng S, **Wong IN\***, Guo Y, Zhang J, Chen J, Yang D, Zhang K, Yao W, Li R, Bai Y, Ding S, Kuang M, Xiao H, Xu D, Collaborative Teaching and Curricular Integration in Pre-Intern Clinical Placements: Insights from the Greater Bay Area (2024). *Adv medical educ pract.*, 15, 1027-1037. (\* first author, IF 1.7, ESCI Q2)
  14. Yu H, Xie Y, Lan L, Ma S, Mok SWF, **Wong IN**, Wang Y, Zhong G, Yuan L, Zhao H, Macrae VE, He S, Chen G, Zhu D, Sirt7 protects against vascular calcification via modulation of reactive oxygen species and senescence of vascular smooth muscle cells (2024). *Free Radic Biol Med.*, 223: 30-41. (fourth author, IF 8.2, SCI Q1)
  15. Xia X, Wu Y, Chen Z, Du D, Chen X, Zhang R, Yan J, **Wong IN\***, Huang R, Colon cancer inhibitory properties of Caulerpa lentillifera polysaccharide and its

- molecular mechanisms based on three-dimensional cell culture model (2024). *Int J Biol Macromol.*, 2024 Apr 12:131574. (\* corresponding author, IF 8.5, SCI Q1)
16. Yang J, Liu J, Kuang W, Lin Y, Zhong S, Kraithong S, Zhang X, **Wong IN\***, Huang R. Structural characterization and ferroptosis-related immunomodulatory of a novel exopolysaccharide isolated from marine fungus *Aspergillus medius* (2024). *Int J Biol Macromol.*, 2024 Mar 6:130703. (\* corresponding author, IF 8.5, SCI Q1)
  17. Wijesekara T, Huang R, **Wong IN\***, Xu B, Insights into immunoregulatory effects of bioactive polysaccharides derived from seaweeds through gut microbiota (2024). *Food Biosci.*, 58: 103800. (\* corresponding author, IF 5.9, SCI Q1)
  18. Wang HM, Lai HJ, Wu AG, Tong Y, Song LL, Lo HH, **Wong IN**, Wong VKW, Law BYK. Melanogenic effects of 5-demethylnobiletin on mouse model of chemical-induced vitiligo (2024). *J. Funct. Foods*, 112: 105962. (seventh author, IF 4.0, SCI Q2)
  19. Zeng J, Lin Q, Xu J, Xu B, **Wong IN\***, Huang R, Oligosaccharides Preparation from *Caulerpa racemosa* var *peltata* with Enzymatic Hydrolysis and Its Mechanism of Immunomodulatory Activity (2024). *食品科學*. (\* corresponding author, CSCD)
  20. Qiu C, Chan JTW, Zhang DW, **Wong IN**, Zeng Y, Law BYK, Mok SWF, Dias IRDSR, Liu W, Liu L, Wong VKW. The potential development of drug-resistance in rheumatoid arthritis patients identified with p53 mutations (2023). *Genes Dis.*, 10(6):2252-2255. (second author, IF 6.9, SCI Q1)
  21. Tam HH, Zhu D, Ho SSK, Vong HW, Wong VKW, Mok SWF, **Wong IN**. Potential enhancement of post-stroke angiogenic response by targeting the oligomeric aggregation of p53 protein (2023). *Front. Cell. Neurosci.*, 17:1193362. (corresponding author, IF 4.2, SCI Q2)
  22. Wu Y, Liu J, Hao H, Hu L, Zhang X, Luo L, Zeng J, Zhang W, **Wong IN**, Huang R. A new polysaccharide from *Caulerpa chemnitzia* induces molecular shifts of immunomodulation on macrophages RAW264.7 (2022). *Food Chem.:X*, 14: 100313. (eighth author, IF 6.5, SCI Q2)
  23. Yang L, Liu J, Xia X, **Wong IN**, Chung SK, El-Seedi HR, Wang B, Hunag R. Sulfated heteropolysaccharides from *Undaria pinnatifida*: Structural characterization and transcript-metabolite profiling of immunostimulatory effects on RAW264. 7 cells (2022). *Food Chem.: X*, 13:100264. (third author, IF 6.1, SCI Q1)
  24. Xia X, Hao H, Zhang X, **Wong IN**, Chung SK, Chen Z, Xu B, Huang R. Immunomodulatory sulfated polysaccharides from *Caulerpa racemosa* var. *peltata* induces metabolic shifts in NF- $\kappa$ B signaling pathway in RAW 264.7 macrophages

- (2021). *Int J Biol Macromol.*, 182:321-332. (third author, IF 8.025, SCI Q1)
25. Monteiro O, Bhaskar A, **Wong IN**, Ng AKM, Baptista-Hon DT. Teaching bioelectricity and neurophysiology to medical students using LabAXON simulations (2021). *Adv Physiol Educ.*, 45(4):702-708. (third author, IF 2.396, SCI Q2)
  26. **Wong IN**, Neo JPS, Oehler J, Schafhauser S, Osman F, Carr SB, Whitby MC (2019). The Fml1-MHF complex suppresses inter-fork strand annealing in fission yeast. *eLife*, 8, e49784. (first author, IF 7.08, SCI Q1)
  27. Morrow CA, Nguyen MO, Fower A, **Wong IN**, Osman F, Bryer C, Whity MC (2017). Inter-fork strand annealing causes genomic deletions during the termination of DNA replication. *eLife*, 6, e25490. (fourth author, IF 7.616, SCI Q1)
  28. **Wong IN**, Sayers JR, Sanders CM (2016). Bacteriophage T5 gene D10 encodes a branch-migration protein. *Scientific Reports*, 6, 39414. (first author, IF 4.259, SCI Q1)
  29. **Wong IN**, Sayers JR, Sanders CM (2013). Characterization of an unusual bipolar helicase encoded by bacteriophage T5. *Nucleic Acids Res*, 41(8), 4587-600. (first author, IF 8.808, SCI Q1)

#### 專利

黃耀南, 鐘靜, 黃日明, 鐘金淑子; 一種多糖的新用途。申請號: CN202510042159.8

# Curriculum Vitae

Name: Io Nam Wong

Position: Assistant Professor

Affiliation: Macau University of Science and Technology

Contact no.: (+853) 88971776

E-mail: inwong@must.edu.mo

ORCID: 0000-0002-4500-1758

Address: Room 209D, Faculty of Medicine, Macau University of Science and Technology, Praia Park Block R, Coloane, Macau



## Biography

---

Dr. Io Nam Wong has been an assistant professor in the Faculty of Medicine at MUST since July 2019. He earned his B.Sc. in Biology from Beijing Normal University in 2006, followed by his M.Sc. in Molecular Medicine (Genetics) at the University of Sheffield where he graduated as the top-ranked student in 2007. He successfully completed his Ph.D. in Medicine at the University of Sheffield in 2012 without any revisions to his thesis. Prior to joining MUST, Dr. Wong held positions as a postdoctoral researcher at both the University of Sheffield and Oxford. He has utilized advanced techniques in protein biochemistry, structural biology, cell biology, and proteomics to discover new DNA replication and repair factors in viruses and humans. These findings were published in well-recognized journals, i.e., *Nucleic Acid Res.*, *eLife*, *Sci. Rep.*

Currently, Dr. Wong's research focuses on discovering and characterizing natural bioactive compounds with translational potential for cancer, neurodegenerative diseases, and immune modulation. In parallel, he investigates medical applications of artificial intelligence, including the modeling of the human full-cycle biological clock to improve our understanding of circadian effects on disease and therapy, to building AI-driven tools for diagnostic support. By bridging natural product discovery with computational and AI methodologies, his work aims to accelerate the translation from molecular insights to clinically actionable interventions. His recent findings have been published in journals like *Nat. Med.*, *Trends Mol. Med.*, *J. Transl. Med.*, *Chin. Med. J.*, *Pharmacol. Res.*, *Biomark. Res.*, *Food Chem.:X* and *Int. J. Biol. Macromol.* He also serves as a member of the ethics commission for life sciences and a former member of the talent development committee's "Big Health" task force of the Macao SAR government.

## Qualifications

---

Jun 2012: PhD in Medicine, University of Sheffield (Outright Pass)

Nov 2007: MSc in Molecular Medicine (Genetics) with Distinction (Rank: 1st),  
University of Sheffield

Jul 2006: BSc in Biology, Beijing Normal University

## Positions

---

Jul 2019 – present: Assistant Professor, Macau University of Science and Technology

Sep 2013 – May 2019: Postdoctoral Research Fellow, University of Oxford

May 2012 – Sep 2013: Postdoctoral Research Fellow, University of Sheffield

Feb 2007 – Aug 2008: Graduate Technician, University of Sheffield

## Selected Awards and Honours

---

2008-2012: Sheffield University Doctoral Fellowship

2006-2007: Macau Postgraduate Scholarship

2002-2006: Macau Tertiary Scholarship

2002: Macau Lotus award

1999: Macau Governor's award

## Current Professional and Social Activities

---

Feb 2025 – present: Member of the ethics commission for life sciences (Macao SAR government)

Jul 2023 – Jun 2025: Member of the task force on “Big Health” under the talent development committee (Macao SAR government)

Mar 2025 – present: : Member of medical ethics committee (MUST)

Aug 2024 – present: Member of clinical research IRB committee (MUST)

Aug 2019 – present: Member of academic integrity committee (MUST)

Aug 2019 – present: Member of student disciplinary committee (MUST)

Jul 2019 – Aug 2020: Member of interdisciplinary teaching laboratory committee (MUST)

## Research Project Grants

---

1. May 2025 – May 2028: FDCT, **Wong Io Nam (PI)**, Investigating the mechanism by which sulfated polysaccharide from *Caulerpa racemosa* modulates DNA

- damage repair pathways to enhance the treatment efficacy of microsatellite stable (MSS) gastric cancer, Project No. 0133/2024/RIA2, MOP\$ 1,700,900
2. Sep 2021 – Sep 2024: FDCT-NSFC, **Wong Io Nam (PI)**, Molecular mechanism of Caulerpa sulfated polysaccharides on immunometabolic reprogramming by targeting COX-2-induced ferroptosis, Project No. 0069/2021/AFJ, MOP\$ 1,600,000
  3. Feb 2022 – Aug 2023: FRG, **Wong Io Nam (PI)**, Characterization of potential novel pro- and anti-viral host factors from proximity-dependent biotin identification (BioID) screen for SV40 host restriction factor FAM111A, Project No. FRG-22-022-FMD, MOP \$100,000
  4. Jun 2024 – Jun 2027: FDCT-AKP, Paul Kwong-Hang Tam (PI), Chen Yan (Co-PI), **Wong Io Nam (Member)**, Integrating regenerative medicine, multi-omics and artificial intelligence platforms to improve the target discovery for new diagnosis and precision intervention of chronic liver fibrosis, Project No. 0011/2023/AKP, MOP\$ 11,917,000
  5. Dec 2022 – Jun 2025: FDCT-ITP, Simon Wing Fai Mok (PI), **Wong Io Nam (Co-PI)**, Vincent Kam Wai Wong (Co-PI), To unveil the modulatory role of p53 aggregates in the progression of Rheumatoid Arthritis, Project No. 0037/2022/ITP, MOP \$425,000
  6. Apr 2022 – Apr 2025: FDCT, Olivia Monteiro (PI), **Wong Io Nam (Co-PI)**, Brian Tomlinson (Co-I), Christopher Wai Kei Lam (Co-I), Effects of Sinopharm BBIBP-CorV and BioNTech mRNA primary vaccine series with homologous and heterologous boosters against SARS-CoV2 variants of concern in a local population in Macao, Project No. 0106/2021/A, MOP \$644,000
  7. Sep 2020 – Sep 2023: FDCT-NSFC, Zhang Kang (PI), **Wong Io Nam (Co-PI)**, Simon Wing Fai Mok (Co-I), Induction of conjunctival stem cells into limbal-like stem cells and corneal reconstruction, Project No. 0007/2020/AFJ, MOP\$ 2,000,000

## **Publications**

---

1. Xia X, Wu Y, Chen Z, Du D, Chen X, Zhang R, Yan J, **Wong IN\***, Huang R, An edible green algae polysaccharide CRVP from *Caulerpa racemosa* var. *peltate* induced apoptosis of liver cancer cells Hepal-6 by regulating glutathione metabolism. *Food Sci Hum Wellness* (2025). DOI: 10.26599/FSHW.2024.9250300. (\* corresponding author, IF 7.4, SCI Q1)
2. Li G, Cheng L, **Wong IN\***, Yin Y, Chen J, Liu L, Zhang K. Predicting healthspan and disease risks through biological age (2025). *Trends Mol Med*, DOI: 10.1016/j.molmed.2025.10.006. (\*first author, IF 13.8, SCI Q1)

3. Zhong J, Chung SK, Han X, Huang R, Xu B, **Wong IN** (2025). *Front Pharmacol*, DOI: 10.3389/fphar.2025.1682025. (Corresponding author, IF 4.8, SCI Q1)
4. Wang K, Liu F, Wu W, Hu H, Shen X, Wang M, Li G, Zeng F, Liu L, **Wong IN**, Liu S, Zou Z, Li B, Li J, Huang X, Jin S, Li Z, Xu H, Chen G, Chen X, Zhu Y, Li P, Feng Z, Wang W. A full life cycle biological clock based on routine clinical data and its impact in health and diseases (2025). *Nat Med*, DOI: 10.1038/s41591-025-04006-w. (second author, IF 50.0, SCI Q1)
5. Liu F, Niu Y, Zhang Q, Kang K, Dong Z, **Wong IN**, Cheng L, Li T, Duan L, Li K, Li G, Hou TW, Fok M, Luo Hu, Chen X, Zhang K, Yin Y. A foundational architecture for AI agents in healthcare (2025). *Cell Rep Med*, DOI: 10.1016/j.xcrm.2025.102374. (sixth author, IF 10.6, SCI Q1)
6. Huang C, Xiao Y, Xu D, **Wong IN**, Patil NG, Chen J, Zhang K, Hu W, Zhang J, Ding S, Kuang M, Xiao H, Feng X. Developing a Student-Centred Curriculum: Insights from Anaesthetic Placement Experiences for Co-Designing in China's Greater Bay Area (2025). *Adv medical educ pract.*, 16, 1695-1704. (second author, IF 1.7, ESCI Q2)
7. Yang L, Mok SWF, Li HH, **Wong IN\***, Yang LJ. DDX27 in cancer: molecular mechanisms, clinical implications, and therapeutic potential (2025). *J Transl Med*, 23, 971. (\* corresponding author, IF 7.5, SCI Q1)
8. Qu L, Tang Y, Wu J, Yun X, Lo HH, Song L, Wang X, Wang H, Zhang R, Liu M, Wang C, Ng JPL, Fu X, **Wong IN\***, Wong VKW, Law BYK, FBXL16: a new regulator of neuroinflammation and cognition in Alzheimer's disease through the ubiquitination-dependent degradation of amyloid precursor protein (2024). *Biomark Res.*, 12, 144. (\* corresponding author, IF 11.5, SCI Q1)
9. **Wong IN**, Monteiro O, Baptista-Hon DT, Wang K, Lu W, Sun Z, Nie S, Yin Y, Leveraging foundation and large language models in medical artificial intelligence (2024). *Chin Med J*. DOI:10.1097/CM9.0000000000003302. (first author, IF 7.3, SCI Q1)
10. Zeng J, Liu J, Zhao N, **Wong IN\***, Huang R, Caulerpa chemnitzia polysaccharide exerts immunomodulatory activity in macrophages by mediating the succinate/PHD2/HIF-1 $\alpha$ /IL-1 $\beta$  pathway, (2024). *Int J Biol Macromol.*, 2024 Oct: 134450. (\* corresponding author, IF 8.5, SCI Q1)
11. Qin B, Fu S, Xu X, Yang J, Wang Y, Wang L, Huang B, Zhang J, Wu W, Lu H, Law BYK, Wang N, **Wong IN\***, Wong VKW, Far-infrared radiation and its therapeutic parameters: A superior alternative for future regenerative medicine? (2024). *Pharmacol Res.*, 208 : 107349. (\* corresponding author, IF 10.5, SCI Q1)
12. Wang XX, Ji X, Lin J, **Wong IN**, Lo HH, Wang J, Qu L, Wong VKW, Chung SK, Law BYK, GPCR-mediated natural products and compounds: Potential

- therapeutic targets for the treatment of neurological diseases (2024). *Pharmacol Res.*, 208: 107395. (second author, IF 10.5, SCI Q1)
13. Zhang J, Tang Y, Feng S, **Wong IN\***, Guo Y, Zhang J, Chen J, Yang D, Zhang K, Yao W, Li R, Bai Y, Ding S, Kuang M, Xiao H, Xu D, Collaborative Teaching and Curricular Integration in Pre-Intern Clinical Placements: Insights from the Greater Bay Area (2024). *Adv medical educ pract.*, 15, 1027-1037. (\* first author, IF 1.7, ESCI Q2)
  14. Yu H, Xie Y, Lan L, Ma S, Mok SWF, **Wong IN**, Wang Y, Zhong G, Yuan L, Zhao H, Macrae VE, He S, Chen G, Zhu D, Sirt7 protects against vascular calcification via modulation of reactive oxygen species and senescence of vascular smooth muscle cells (2024). *Free Radic Biol Med.*, 223: 30-41. (fourth author, IF 8.2, SCI Q1)
  15. Xia X, Wu Y, Chen Z, Du D, Chen X, Zhang R, Yan J, **Wong IN\***, Huang R, Colon cancer inhibitory properties of *Caulerpa lentillifera* polysaccharide and its molecular mechanisms based on three-dimensional cell culture model (2024). *Int J Biol Macromol.*, 2024 Apr 12:131574. (\* corresponding author, IF 8.5, SCI Q1)
  16. Yang J, Liu J, Kuang W, Lin Y, Zhong S, Kraithong S, Zhang X, **Wong IN\***, Huang R. Structural characterization and ferroptosis-related immunomodulatory of a novel exopolysaccharide isolated from marine fungus *Aspergillus medius* (2024). *Int J Biol Macromol.*, 2024 Mar 6:130703. (\* corresponding author, IF 8.5, SCI Q1)
  17. Wijesekara T, Huang R, **Wong IN\***, Xu B, Insights into immunoregulatory effects of bioactive polysaccharides derived from seaweeds through gut microbiota (2024). *Food Biosci.*, 58: 103800. (\* corresponding author, IF 5.9, SCI Q1)
  18. Wang HM, Lai HJ, Wu AG, Tong Y, Song LL, Lo HH, **Wong IN**, Wong VKW, Law BYK. Melanogenic effects of 5-demethylnobiletin on mouse model of chemical-induced vitiligo (2024). *J. Funct. Foods*, 112: 105962. (seventh author, IF 4.0, SCI Q2)
  19. Zeng J, Lin Q, Xu J, Xu B, **Wong IN\***, Huang R, Oligosaccharides Preparation from *Caulerpa racemosa* var *peltate* with Enzymatic Hydrolysis and Its Mechanism of Immunomodulatory Activity (2024). *食品科學*. (\* corresponding author, CSCD)
  20. Qiu C, Chan JTW, Zhang DW, **Wong IN**, Zeng Y, Law BYK, Mok SWF, Dias IRDSR, Liu W, Liu L, Wong VKW. The potential development of drug-resistance in rheumatoid arthritis patients identified with p53 mutations (2023). *Genes Dis.*, 10(6):2252-2255. (second author, IF 6.9, SCI Q1)
  21. Tam HH, Zhu D, Ho SSK, Vong HW, Wong VKW, Mok SWF, **Wong IN**. Potential enhancement of post-stroke angiogenic response by targeting the oligomeric

- aggregation of p53 protein (2023). *Front. Cell. Neurosci.*, 17:1193362. (corresponding author, IF 4.2, SCI Q2)
22. Wu Y, Liu J, Hao H, Hu L, Zhang X, Luo L, Zeng J, Zhang W, **Wong IN**, Huang R. A new polysaccharide from *Caulerpa chemnitzia* induces molecular shifts of immunomodulation on macrophages RAW264.7 (2022). *Food Chem.:X*, 14: 100313. (eighth author, IF 6.5, SCI Q2)
  23. Yang L, Liu J, Xia X, **Wong IN**, Chung SK, El-Seedi HR, Wang B, Hunag R. Sulfated heteropolysaccharides from *Undaria pinnatifida*: Structural characterization and transcript-metabolite profiling of immunostimulatory effects on RAW264. 7 cells (2022). *Food Chem.: X*, 13:100264. (third author, IF 6.1, SCI Q1)
  24. Xia X, Hao H, Zhang X, **Wong IN**, Chung SK, Chen Z, Xu B, Huang R. Immunomodulatory sulfated polysaccharides from *Caulerpa racemosa* var. *peltata* induces metabolic shifts in NF- $\kappa$ B signaling pathway in RAW 264.7 macrophages (2021). *Int J Biol Macromol.*, 182:321-332. (third author, IF 8.025, SCI Q1)
  25. Monteiro O, Bhaskar A, **Wong IN**, Ng AKM, Baptista-Hon DT. Teaching bioelectricity and neurophysiology to medical students using LabAXON simulations (2021). *Adv Physiol Educ.*, 45(4):702-708. (third author, IF 2.396, SCI Q2)
  26. **Wong IN**, Neo JPS, Oehler J, Schafhauser S, Osman F, Carr SB, Whitby MC (2019). The Fml1-MHF complex suppresses inter-fork strand annealing in fission yeast. *eLife*, 8, e49784. (first author, IF 7.08, SCI Q1)
  27. Morrow CA, Nguyen MO, Fower A, **Wong IN**, Osman F, Bryer C, Whity MC (2017). Inter-fork strand annealing causes genomic deletions during the termination of DNA replication. *eLife*, 6, e25490. (fourth author, IF 7.616, SCI Q1)
  28. **Wong IN**, Sayers JR, Sanders CM (2016). Bacteriophage T5 gene D10 encodes a branch-migration protein. *Scientific Reports*, 6, 39414. (first author, IF 4.259, SCI Q1)
  29. **Wong IN**, Sayers JR, Sanders CM (2013). Characterization of an unusual bipolar helicase encoded by bacteriophage T5. *Nucleic Acids Res*, 41(8), 4587-600. (first author, IF 8.808, SCI Q1)

## Patent

---

**Wong IN**, Zhong J, Huang R, Chung SK. A Novel Use of a Polysaccharide. Application no.: CN202510042159.8